Navigation Links
Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
Date:3/23/2009

SAN MATEO¿ Calif.¿ March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at 10:30 a.m. EDT on Sunday, March 29, at the American College of Cardiology's (ACC) 58th Annual Scientific Session in Orlando, Fla.

John R. Teerlink, M.D., professor of medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center will present the results from the multicenter, international Pre-RELAX-AHF study as part of an ACC special session entitled "Late-Breaking Clinical Trials I: Congestive Heart Failure."

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure.

About Corthera

Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. For more information, visit www.corthera.com.

    Contact:      Andreas Marathovouniotis or David Schull
                  Russo Partners
                  212.845.4235
                  andreas.marathis@russopartnersllc.com
                  david.schull@russopartnersllc.com


'/>"/>
SOURCE Corthera
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Mass. , Feb. 9, 2016   AllCare ... The Joint Commission,s Gold Seal of Approval ® ... compliance with its performance standards. The Gold Seal of ... reflects an organization,s commitment to providing safe and effective ... AllCare Plus Pharmacy underwent a rigorous on-site survey ...
(Date:2/9/2016)... The global prefilled syringes market accounted for $3,905.1 million ... with a CAGR of 12.9% during 2015-2020. Among the ... global prefilled syringes market, with 90.1% share in 2014. ... global market of prefilled syringes is up surging with ... demand for vaccines, increasing prevalence of chronic and lifestyle ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016  Increasingly, health ... monitoring their vital signs with wireless technology. With the ... can automate patient oversight and remotely detect problems before ... vital signs across in-hospital environments. the ... the United States . --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Everseat has joined the award-winning Allscripts ... physicians. The integration will enable Allscripts users to post open appointments to the ... app. , The partnership gives Everseat substantial added power to help Allscripts meet ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics, who is celebrating their 25th ... humble beginnings to being an internationally recognized leader in their industry. , "We are ... Charlie Lawrence, President of Workrite. “Workrite recognized the importance of good ergonomics before ...
(Date:2/10/2016)... ... February 09, 2016 , ... Western University ... free oral screenings to 150 children in kindergarten through third grade at Hurley ... Dental Medicine joined Chinese American Dental Society of Southern California volunteers for Give ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... It’s that ... Traci Davis, the new president of the Interscholastic Athletic Association of Maryland (IAAM), Hall ... well how quickly fitness goals are cast aside. , That’s why one of her ...
(Date:2/9/2016)... ... , ... February is Heart Awareness Month, and to celebrate Health Quest Chiropractic ... the American Heart Association, New Mexico chapter. , A Heart Rate Variability (HRV) scan ... INSiGHT Pulse Wave Profiler utilizes a non-invasive technology to determine a heart’s ability to ...
Breaking Medicine News(10 mins):